SCbio’s life sciences accelerator, SCbioDrive, announces Spring 2025 cohort of oncology and neuroscience startups

Six emerging life science startups from South Carolina to Ireland to receive guidance, mentoring and business-focused curriculum modules taught by industry experts, including Deloitte, Eli Lilly, Inspire Agency, Maynard Nexsen, Medpoint and VentureSouth.

SCbio, in partnership with The Massachusetts Biotechnology Council (MassBio), has selected six emerging life sciences companies to participate in the Spring 2025 SCbioDrive Accelerator cohort.

An annual program, SCbioDrive will lead six seed-stage life sciences companies through an eight-week hybrid program designed to advance their platforms and technologies through expert business curricula, industry guidance and mentorship – all at no cost.

The program will end in June with a Demo Day in Charleston, S.C., where cohort companies will present to a curated group of potential investors and industry leaders.

SCbioDrive Spring 2025 Cohort

Lipo-ImmunoTech, LLC (Mount Pleasant, S.C.) was founded to advance anti-cancer strategies that also show promise in treating neurodegenerative disorders like Alzheimer’s disease. Strong mechanistic data support the methods and have the potential to improve patient health significantly. The company specializes in innovative anti-cancer approaches that utilize lipid metabolism/signaling and immunotherapy. Lipo-Immuno Tech offers a unique, two-pronged therapeutic approach with specialized expertise and leadership by targeting lipid metabolism/signaling and boosting the body’s natural anti-cancer immune responses.

Genicity (Galway, Ireland) is pioneering a new frontier in T-cell immunotherapy for incurable diseases. It is on track to deliver early clinical data in small-cell lung cancer and partners with top cancer centers globally.

OsteoCure Therapeutics, Inc. (Durham, N.C.) develops advanced therapies to address unmet needs in bone health and regeneration. The company specializes in novel combination products that accelerate healing and improve outcomes in orthopedic care.

Sebastian Biopharma (Beverly, M.A.) is focused on developing biologics to enhance immune checkpoint therapies for cancer treatment. Its lead product, iTAP, is advancing through the lead compound nomination stage using a modular antibody-oligonucleotide conjugate platform.

SiNON Nano Sciences (Durham, N.C.) uses patented carbon-based nanoparticles to deliver drugs across the blood-brain barrier. Their technology enhances precision treatment for CNS diseases, oncology, and other difficult-to-treat conditions.

TATUM bioscience (Sherbrooke, Canada) is developing a first-in-class nanofilament vaccine immunotherapy to improve cancer treatment. This approach aims to significantly increase response rates by revealing cancer cells and activating strong, durable immune responses.

About SCbio

SCbio is the definitive, unifying leader in South Carolina’s life sciences sector, fostering authentic collaboration and innovation across academia, startups, government and established enterprises. As a member-driven economic development organization, SCbio represents more than 1,000 organizations employing more than 87,000 professionals. Our members are unified by a mission to positively impact humanity through science across the ecosystem of advanced and specialty manufacturing; digital health and the data frontier; and cutting-edge health specializations. For additional information about SCbio and the life sciences industry or to become a member, visit www.SCbio.org.